Clinical Trials Browser

NIH × Gliosarcoma × Nivolumab × Clear all

NCT04817254 2026-03-18

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Phase 2 Active not recruiting

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT04396860 2026-03-05

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Phase 2/3 Completed

159 enrolled 17 charts

Gliosarcoma

NCT02311920 2023-01-10

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Phase 1 Completed

Gliosarcoma